Dr. Ewa Wysokinska discussed how thrombosis affects 20% of cancer patients, especially in GI, ovarian, brain, and renal cancers. DOACs like apixaban are effective with lower bleeding risk vs. heparin. Extended low-dose apixaban is safe. The Khorana score aids risk prediction. Acquired inhibitors need targeted therapy and cancer control.